InSphero AG

InSphero AG develops advanced 3D in vitro models for non-animal drug testing, providing reliable cell culture systems that mimic human biology for enhanced preclinical research and decision-making in pharmaceutical development. Founded in 2009 and headquartered in Zurich, Switzerland, InSphero AG focuses on creating innovative solutions for drug discovery. The company is led by CEO Jan Lichtenberg and has completed 8 funding deals, most recently raising USD 10. 00 mn in a Series D round on January 19, 2023, bringing the total amount raised to USD 10.

00 mn. InSphero specializes in advanced 3D in vitro models that assist in non-animal drug testing. Their flagship product, the Akura™ Plates, enhances automation and efficiency in cell culture, allowing high-throughput analysis crucial for pharmaceutical and biotechnological applications. They serve pharmaceutical companies, biotech firms, and academic institutions globally, promoting ethical alternatives to traditional animal testing.

InSphero generates revenue through direct sales of its 3D in vitro models and associated services, primarily to pharmaceutical and biotech clients. The revenue model often involves long-term partnerships where clients access customized products and services, including subscription-based offerings, reflecting the advanced features of products like the Akura™ Plates. In January 2023, InSphero AG secured grant funding from Eureka-Eurostars, with participation from Bpifrance Investissement and Innosuisse, aimed at advancing a cancer research project. The company plans to leverage this funding to design and launch new products, targeting expansion into additional markets in North America and Asia by the end of 2024.